Special Offers
100% Performance Guaranteed
| Description | |
|---|---|
| Catalogue Number | MAB4132-25UG |
| Brand Family | Chemicon® |
| Trade Name |
|
| Description | Anti-BRCA-1, clone BR64 |
| Product Information | |
|---|---|
| Format | Purified |
| Presentation | Liquid in 0.02M phosphate buffer, 0.25M NaCl, containing 0.1% sodium azide as a preservative. |
| Quality Level | MQ100 |
| Applications | |
|---|---|
| Application | Anti-BRCA1 Antibody, clone BR64 is a high quality Mouse Monoclonal Antibody for the detection of BRCA1 & has been validated in IP & WB. |
| Key Applications |
|
| Application Notes | Immunoprecipitation Western blot Optimal working dilutions must be determined by end user. |
| Biological Information | |
|---|---|
| Immunogen | Purified polypeptide representing a 100-amino acid segment of the amino terminus of the BRCA1 gene product. |
| Clone | BR64 |
| Concentration | Please refer to lot specific datasheet. |
| Host | Mouse |
| Specificity | The breast cancer susceptibility gene, BRCA1*, is located on chromosome 17 (at q21), and is mutated in the majority of heritable breast cancers. The mutations within the coding region occur throughout the gene with little apparent clustering. The majority of BRCA1 mutations result in shortened BRCA1 gene products, creating a need for an amino-terminal marker. Antibody MAB4132 recognizes both the full-length and mutated (shortened) forms of BRCA1 in breast cancer cell lines. It also recognizes over-expressed protein in transiently transfected Cos cells. A single cross-reacting protein of approximately 27 kDa is also seen upon immunoprecipitation. No other cross-reacting proteins are detected. BRAC1 is 220kDa. *BRCA1 is covered under U.S. patents 5,747,282, 5,753,441 and 6,162,897. |
| Isotype | IgG1κ |
| Species Reactivity |
|
| Antibody Type | Monoclonal Antibody |
| Entrez Gene Number |
|
| Entrez Gene Summary | This gene encodes a nuclear phosphoprotein that plays a role in maintaining genomic stability and acts as a tumor suppressor. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as BASC for BRCA1-associated genome surveillance complex. This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complex. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants have been described for this gene but only some have had their full-length natures identified. |
| Gene Symbol |
|
| UniProt Number |
|
| UniProt Summary | FUNCTION: SwissProt: P38398 # Plays a central role in DNA repair by facilitating cellular response to DNA repair. Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. Involved in transcriptional regulation of P21 in response to DNA damage. Required for FANCD2 targeting to sites of DNA damage. May function as a transcriptional regulator. Mediates E2-dependent ubiquitination. Inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation. SIZE: 1863 amino acids; 207721 Da SUBUNIT: Part of the BRCA1-associated genome surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, ATM, BLM, PMS2 and the RAD50-MRE11-NBN protein complex. This association could be a dynamic process changing throughout the cell cycle and within subnuclear domains. CTIP interacts specifically with the BRCT domains. Interacts with RNA polymerase II holoenzyme. Interacts with SMC1A and COBRA1/NELFB. Binds BRIP1 through the BRCT domains. Interacts with ubiquitinated FANCD2. Interacts with BAP1. Interacts with DCLRE1C/Artemis and CLSPN. Interacts with histone H2AFX and this requires phosphorylation of H2AFX on Ser-139. Interacts with CHEK1/CHK1. Interacts with BRCC3. Interacts through its BRCT domains with phosphorylated ACACA and prevents its dephosphorylation. SUBCELLULAR LOCATION: Nucleus. DOMAIN: SwissProt: P38398 The RING-type zinc finger domain interacts with BAP1. PTM: Phosphorylated in response to IR, UV, and various stimuli that cause checkpoint activation, probably by ATM or ATR. DISEASE: "SwissProt: P38398 # Defects in BRCA1 are a cause of genetic susceptibility to breast cancer (BC) [MIM:113705, 114480]. BC is an extremely common malignancy, affecting one in eight women during their lifetime. A positive family history has been identified as major contributor to risk of development of the disease, and this link is striking for early-onset breast cancer. Mutations in BRCA1 are thought to be responsible for 45% of inherited breast cancer. Moreover, BRCA1 carriers have a 4-fold increased risk of colon cancer, whereas male carriers face a 3-fold increased risk of prostate cancer. Cells lacking BRCA1 show defects in DNA repair by homologous recombination. & Defects in BRCA1 are a cause of genetic susceptibility to breast-ovarian cancer (BOC) [MIM:113705]. Mutations in BRCA1 are thought to be responsible for more than 80% of inherited breast- ovarian cancer. & Defects in BRCA1 are a cause of genetic susceptibility to ovarian cancer [MIM:113705]." SIMILARITY: Contains 2 BRCT domains. & Contains 1 RING-type zinc finger. |
| Product Usage Statements | |
|---|---|
| Quality Assurance | Tested |
| Usage Statement |
|
| Storage and Shipping Information | |
|---|---|
| Storage Conditions | Maintain refrigerated at 2-8°C in undiluted aliquots for up to 12 months. |
| Packaging Information | |
|---|---|
| Material Size | 25 μg |